|
業務類別
|
Biotechnology |
|
業務概覽
|
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential. |
| 公司地址
| 611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 415 910-5717 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.quincetx.com |
| 員工數量
| 36 |
| Mr. Brendan Hannah |
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer, Principal Financial Officer and Principal Accounting Officer |
美元 425.00K |
23/04/2025 |
| Dr. Charles S. Ryan, J.D.,PhD |
President |
美元 500.00K |
23/04/2025 |
| Dr. Dirk Thye, M.D. |
Chief Executive Officer, Chief Medical Officer and Director |
美元 550.00K |
23/04/2025 |
|
|
| Mr. Christopher J. Senner |
Independent Director |
23/04/2025 |
| Dr. Dirk Thye, M.D. |
Chief Executive Officer, Chief Medical Officer and Director |
23/04/2025 |
| Mr. David A. Lamond |
Chairman of the Board |
23/04/2025 |
|
|
|
|
